Targeting myeloid-derived suppressor cells for cancer therapy

The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongchao Tang, Hao Li, Zhijun Sun
Formato:	article
Lenguaje:	EN
Publicado:	China Anti-Cancer Association 2021
Materias:	immunotherapy immunosuppression mdscs icb compounds Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/277836c16d664728bdeac45eeca03939
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:277836c16d664728bdeac45eeca03939
record_format	dspace
spelling	oai:doaj.org-article:277836c16d664728bdeac45eeca039392021-11-30T11:27:44ZTargeting myeloid-derived suppressor cells for cancer therapy2095-394110.20892/j.issn.2095-3941.2020.0806https://doaj.org/article/277836c16d664728bdeac45eeca039392021-11-01T00:00:00Zhttp://www.cancerbiomed.org/index.php/cocr/article/view/1895https://doaj.org/toc/2095-3941The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some patients. The main obstacle to inducing effective antitumor immune responses with ICB is the development of an immunosuppressive tumor microenvironment. Myeloid-derived suppressor cells (MDSCs), as major immune cells that mediate tumor immunosuppression, are intimately involved in regulating the resistance of cancer patients to ICB therapy and to clinical cancer staging and prognosis. Therefore, a combined treatment strategy using MDSC inhibitors and ICB has been proposed and continually improved. This article discusses the immunosuppressive mechanism, clinical significance, and visualization methods of MDSCs. More importantly, it describes current research progress on compounds targeting MDSCs to enhance the antitumor efficacy of ICB.Hongchao TangHao LiZhijun SunChina Anti-Cancer AssociationarticleimmunotherapyimmunosuppressionmdscsicbcompoundsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Biology & Medicine, Vol 18, Iss 4, Pp 992-1009 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy immunosuppression mdscs icb compounds Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy immunosuppression mdscs icb compounds Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hongchao Tang Hao Li Zhijun Sun Targeting myeloid-derived suppressor cells for cancer therapy
description	The emergence and clinical application of immunotherapy is considered a promising breakthrough in cancer treatment. According to the literature, immune checkpoint blockade (ICB) has achieved positive clinical responses in different cancer types, although its clinical efficacy remains limited in some patients. The main obstacle to inducing effective antitumor immune responses with ICB is the development of an immunosuppressive tumor microenvironment. Myeloid-derived suppressor cells (MDSCs), as major immune cells that mediate tumor immunosuppression, are intimately involved in regulating the resistance of cancer patients to ICB therapy and to clinical cancer staging and prognosis. Therefore, a combined treatment strategy using MDSC inhibitors and ICB has been proposed and continually improved. This article discusses the immunosuppressive mechanism, clinical significance, and visualization methods of MDSCs. More importantly, it describes current research progress on compounds targeting MDSCs to enhance the antitumor efficacy of ICB.
format	article
author	Hongchao Tang Hao Li Zhijun Sun
author_facet	Hongchao Tang Hao Li Zhijun Sun
author_sort	Hongchao Tang
title	Targeting myeloid-derived suppressor cells for cancer therapy
title_short	Targeting myeloid-derived suppressor cells for cancer therapy
title_full	Targeting myeloid-derived suppressor cells for cancer therapy
title_fullStr	Targeting myeloid-derived suppressor cells for cancer therapy
title_full_unstemmed	Targeting myeloid-derived suppressor cells for cancer therapy
title_sort	targeting myeloid-derived suppressor cells for cancer therapy
publisher	China Anti-Cancer Association
publishDate	2021
url	https://doaj.org/article/277836c16d664728bdeac45eeca03939
work_keys_str_mv	AT hongchaotang targetingmyeloidderivedsuppressorcellsforcancertherapy AT haoli targetingmyeloidderivedsuppressorcellsforcancertherapy AT zhijunsun targetingmyeloidderivedsuppressorcellsforcancertherapy
_version_	1718406610527715328

Targeting myeloid-derived suppressor cells for cancer therapy

Ejemplares similares